clinical trials retatrutide A new trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes retatrutide safety clinical trial retatrutide

Taking NAC provides the raw materials, while taking glutathione (especially in liposomal form) provides the finished product directly to the cells

These are model readouts in animals, not human safety findings

Key Takeaways Retatrutide targets three hormones (GLP-1, GIP, glucagon), tirzepatide targets two (GLP-1, GIP), and semaglutide targets one (GLP-1) At 68 weeks, retatrutide achieved 28.7% average weight loss, tirzepatide approximately 22%, and semaglutide around 17% on the highest doses Side effects are similar across all three medications, mainly digestive issues like nausea and diarrhoea Retatrutide is not yet approved and won't be available until mid-2026 at the earliest Retatrutide is not yet approved and is not currently available in the UK Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available now in the UK through NHS or private providers By entering I agree to the Terms and Conditions

The 2021 Akar paper in Journal of Obstetrics and Gynaecology documented anti-proliferative activity of small-molecule NNMT inhibitors in HeLa cell systems (PMID 33645410)

Its important to note that current interest in the peptides applications for arthritis remains within the realm of scientific research, and it is not yet approved for clinical use in treating this condition

But we are also seeing other injectable medications in testing that might be more powerful than whats already on the market